ArticleParasites & vectors2025
Antigen B from Echinococcus granulosus regulates autophagy-mediated macrophage polarization to alleviate immune thrombocytopenia.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by a low platelet count (< 100 × 10
methodsThis study analyzed blood samples acquired from pediatric patients with ITP and healthy controls. Furthermore, the levels of inflammatory cytokines in plasma, as well as macrophage surface markers and autophagy-related markers [microtubule-associated protein 1 light chain 3 (LC3) and sequestosome-1 (p62)] in peripheral blood mononuclear cells (PBMCs) were evaluated. Moreover, the ITP model was successfully established after immunization with an anti-CD41 antibody and treatment with AgB in vivo. Platelet counts and hemorrhagic symptoms were continuously examined, while plasma inflammatory cytokine levels and the expression of pertinent indicators in the spleen were assessed. RAW264.7 macrophages and lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages were treated with AgB to assess the expression of relevant markers in an in vitro experiment. The mechanism by which AgB regulates LC3 and p62 levels to inhibit LPS-induced macrophages was investigated. Lastly, autophagy inhibitors were administered to evaluate the specific stage of autophagy affected by AgB.
resultsAgB ameliorated hemorrhage and increased platelet counts in ITP murine models while decreasing the M1/M2 macrophage ratio. AgB therapy increased macrophage autophagic flux in vivo and in vitro. To elucidate the effects of AgB on various stages of autophagy, macrophages were treated with two autophagy inhibitors: 3-methyladenine (3-MA) and bafilomycin A1. This study revealed that AgB primarily acts by influencing the expression of LC3II/LC3I and p62, increasing the formation of autophagosomes and enabling lysosomes to identify and consume autophagosomes more accurately. AgB also inhibits macrophage polarization towards M1. These results suggested that AgB reduced hemorrhage in the ITP mouse model by regulating autophagy-mediated macrophage polarization.
conclusionsThis study showed that AgB alleviates ITP by restoring autophagy flux, inhibiting M1 macrophage polarization, and modulating immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.